Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T21:57:39.887Z.
Calculation as of: 2026-10-06T21:57:39.887Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 127c42f84a692115bc317292f5e8c44ad9cea602a51c3ca4b81ff92f7edcc32f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$82.47M
Price/OCF Ratio
N/A
TTM Avg
17.74
3Y Avg
16.00
5Y Avg
17.53
Market Cap
$82.53M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$79.61M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$79.03M
Price/OCF Ratio
N/A
TTM Avg
786.57
3Y Avg
786.57
5Y Avg
786.57
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nutriband Inc. (NTRB) | $81.20M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $81.22M | N/A | 111.15 | 111.15 | 111.15 |
| Humacyte, Inc. (HUMA)vs › | $80.30M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $82.29M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | N/A | 17.74 | 16.00 | 17.53 |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.53M | N/A | N/A | N/A | N/A |
| ProMIS Neurosciences, Inc. (PMN)vs › | $82.59M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | N/A | 786.57 | 786.57 | 786.57 |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
